HBM HLDGS LTD DL-000025 Total Liabilities

Latest as of December 2025: €133.14 Million EUR ≈ $155.66 Million USD

HBM HLDGS LTD DL-000025 total liabilities. Based on the latest financial reports, HBM HLDGS LTD DL-000025 (6XY) has total liabilities worth €133.14 Million EUR (≈ $155.66 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See HBM HLDGS LTD DL-000025 defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Total Liabilities of HBM HLDGS LTD DL-000025 (2021–2025)

Total liabilities of HBM HLDGS LTD DL-000025 from 2021 to 2025. This chart illustrates how HBM HLDGS LTD DL-000025's total liabilities have evolved over time, based on quarterly financial data.

HBM HLDGS LTD DL-000025 Competitors by Total Liabilities

The table below lists competitors of HBM HLDGS LTD DL-000025 ranked by their total liabilities.

Company Country Total Liabilities
COSMO Pharmaceuticals SA
LSE:0RGI
UK £121.91 Million
OMH SCIENCE Group Co Ltd
SHE:300486
China CN¥1.38 Billion
Shandong Oriental Ocean Sci-Tech Co Ltd
SHE:002086
China CN¥311.73 Million
Dalian Dalicap Technology Co Ltd
SHE:301566
China CN¥82.07 Million
Yapp Automotive Systems Co Ltd
SHG:603013
China CN¥2.44 Billion
Nichidenbo Corp
TW:3090
Taiwan NT$8.33 Billion
Shenzhen Xinyichang Technology Co. Ltd. A
SHG:688383
China CN¥1.58 Billion
SIGNATUREGLOBAL (INDIA) LIMITED
NSE:SIGNATURE
India Rs138.47 Billion

Liability Composition Analysis (2021–2025)

This chart breaks down HBM HLDGS LTD DL-000025's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of HBM HLDGS LTD DL-000025.

Liquidity & Leverage Metrics

HBM HLDGS LTD DL-000025 Total Liabilities Ratios Explained

HBM HLDGS LTD DL-000025 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 5.17 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.36 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.27 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how HBM HLDGS LTD DL-000025's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for HBM HLDGS LTD DL-000025 (2021–2025)

The table below shows the annual total liabilities of HBM HLDGS LTD DL-000025 from 2021 to 2025.

Year Total Liabilities Change
2025-12-31 €133.14 Million
≈ $155.66 Million
+46.37%
2024-12-31 €90.96 Million
≈ $106.34 Million
-16.43%
2023-12-31 €108.85 Million
≈ $127.26 Million
-22.04%
2022-12-31 €139.62 Million
≈ $163.23 Million
+134.87%
2021-12-31 €59.45 Million
≈ $69.50 Million
--

About HBM HLDGS LTD DL-000025

F:6XY Germany Biotechnology
Market Cap
$1.14 Billion
€972.87 Million EUR
Market Cap Rank
#8061 Global
#1093 in Germany
Share Price
€1.16
Change (1 day)
-2.52%
52-Week Range
€1.03 - €1.78
All Time High
€1.93
About

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company i… Read more